

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450, on the date shown below.

Dated: January 28, 2004

Signature: 

(Sharon M. Switich)



**AMENDMENT AFTER FINAL  
EXPEDITED PROCEDURE  
GROUP ART UNIT 1646**

Docket No.: 01017/36917A

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Medlock et al.

**RECEIVED**

Application No.: 09/810,927

Group Art Unit: 1646 FEB 16 2004

Filed: March 16, 2001

Examiner: J. Anders *TECH OFFICE*

For: IL-17 RECEPTOR LIKE MOLECULES AND  
USES THEREOF

**AMENDMENT UNDER 37 C.F.R. §1.116 AND  
SUBMISSION UNDER 37 C.F.R. §1.114**

**MS AF**  
Commissioner for Patents  
Alexandria, VA 22313

Dear Sir:

This amendment is filed in response to a final office action mailed July 28, 2003 (hereinafter the "Action"), wherein claims 4-6, 10-14, 59-61 and 93-95 were rejected under 35 U.S.C. §102(a) over Shi *et al.* (WO 99/14240). Those same claims were also rejected under 35 U.S.C. § 102(e) over Shaughnessy (US 2002/0102639). Claims 1, 3-12, 14, 59-61, 74, 75 and 90-96 were provisionally rejected under 35 U.S.C. § 101 for statutory-type double patenting and under the judicially created doctrine of obviousness-type double patenting. Reconsideration and withdrawal of the rejections are respectfully requested in view of the following amendment and remarks. This amendment is timely filed with a petition and fee for a three-month extension of time. A Request for Continued Examination is being filed herewith.

The amendments to the specification begin at page 2

The listing of claims begins at page 4.

The remarks begin at page 9.